Trends in hospitalizations with antibiotic-resistant infections: U.S., 1997-2006

Public Health Reports

Volumn 126, Issue 3, 2011, Pages 354-360

  Mainous III, Arch G ^a   Diaz, Vanessa A ^a   Matheson, Eric M ^a   Gregorie, Seth H ^a   Hueston, William J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABSCESS; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC RESISTANT INFECTION; ARTICLE; BACTERIAL INFECTION; CARBUNCLE; CELLULITIS; CHILD; DISEASE ASSOCIATION; ENDOCARDITIS; FEMALE; FURUNCULOSIS; GRAFT INFECTION; HEALTH INSURANCE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFECTION; INTESTINE INFECTION; KIDNEY INFECTION; LENGTH OF STAY; LYMPHADENITIS; MAJOR CLINICAL STUDY; MYOCARDITIS; OSTEOSCLEROSIS; PELVIC INFLAMMATORY DISEASE; PERITONEAL AND RETROPERITONEAL INFECTIONS; PERITONITIS; PNEUMONIA; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; PROSTHESIS INFECTION; SEPTICEMIA; SKIN ULCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNITED STATES; URINARY TRACT INFECTION; AGE DISTRIBUTION; MALE; RISK FACTOR; STATISTICS;

AGE DISTRIBUTION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 79957821591     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335491112600309     Document Type: Article

References (18)

1. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Sheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Disease Society of America. Clin Infect Dis 2008;46:155-64.
2. Smolinski MS, Hamburg MA, Lederberg J, editors. Microbial threats to health: emergence, detection, and response. Washington: Institute of Medicine; 2003.
3. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Alexandria (VA): Infectious Diseases Society of America; 2004.
4. Wang SA, Harvey AB, Conner SM, Zaidi AA, Knapp JS, Whittington WL, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007;147:81-8.
5. Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009;302:859-65.
6. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 2008;168:1984-92.
7. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1988-2007. J Antimicrob Chemother 2009;64:169-74.
8. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163-70.
9. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis 2009;49:65-71.
10. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 2008;46:787-94.
11. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis 2007;13:236-42.
12. Research Triangle Institute. SUDAAN®: Version 10.0. Research Triangle Park (NC): Research Triangle Institute; 2010.
13. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007;13:1840-6.
14. Centers for Disease Control and Prevention (US). National Nosocomial Infections Surveillance System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
15. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospitalacquired clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004;189:1585-9.
16. Roberts RR, Hota B, Ahmad I, Scott RD II, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49:1175-84.
17. Institute of Medicine. Antimicrobial drug resistance: issues and options. Washington: National Academies Press; 1998.
18. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.